IngredientsBrassicasterol is a naturally occurring phytosterol belonging to the 4-desmethyl sterol subclass. Its systematic chemical name is 24-methylcholest-5,22-dien-3β-ol, and it is a 28-carbon sterol synthesised by several unicellular algae (phytoplankton) and some terrestrial plants, such as rape (Brassica napus). An alternative systematic name used in the IUPAC and chemical database literature is (22E)-ergosta-5,22-dien-3β-ol. Formally, it is classified as a 3β-sterol that is (22E)-ergosta-5,22-diene substituted by a hydroxy group at position 3β, and is a phytosterol found in marine algae, fish, and rapeseed oil.
The chemical structure of phytosterols is very similar to that of cholesterol, with a C-5 double bond and a 3β-hydroxyl group, but with structural modifications of the C-24 side chain. In the case of brassicasterol, these modifications consist of both a 24-methyl group and a C-22 double bond in the side chain. Brassicasterol shares the C-22 unsaturation within the side chain with ergosterol and stigmasterol. Structurally, it is closely related to ergosterol: removing carbon C-242 and the hydrogens from carbons 22 and 23, and inverting the stereochemistry at C-24 yields brassicasterol (ergosta-5,22-dien-3β-ol); further removal of hydrogens from carbons 7 and 8 from brassicasterol yields ergosterol (ergosta-5,7,22-trien-3β-ol).
Based on the number of CH₃-substituents at the C-4 position in the carbon backbone, phytosterols can be classified into three categories: 4-demethyl phytosterols, 4-monomethyl phytosterols, and 4,4-dimethyl phytosterols. The most widely reported natural 4-demethyl phytosterols are β-sitosterol, stigmasterol, campesterol, and brassicasterol.
Physical properties: Brassicasterol has a low water solubility and, as a consequence, a high octanol-water partition coefficient. This means that in most environmental systems brassicasterol will be associated with the solid phase. In anaerobic sediments and soils, brassicasterol is stable for many hundreds of years, enabling it to be used as an indicator of past algal production.
Regulatory status: Brassicasterol is one of the ingredients in stigmasterol-rich plant sterols, designated as Number E499 in the European numbering system.
Brassicasterol is produced by two principal categories of organisms: unicellular marine algae and members of the Brassicaceae (cabbage) plant family, along with scattered appearances in other foods.
The principal source of brassicasterol in the environment is from marine algae. Brassicasterol is a phytosterol often present in algae such as phytoplankton. In marine organic matter, brassicasterol and dinosterol have been associated with a wide range of algal groups such as diatoms and dinoflagellates, and have been often used as open-water phytoplankton biomarker proxies. The microalga Phaeodactylum tricornutum, a widely studied marine diatom, is one notable algal species in which brassicasterol accumulates as a major sterol constituent and has been the subject of pharmaceutical extraction research.
As the name suggests, brassicasterols (24-methyl-cholesta-5,22-dien-3β-ol and related sterols) are best known from the Brassica family of plants, but they are also common constituents of marine algae (phytoplankton). Brassicasterol is also present in rapeseed oil, along with campesterol. β-Sitosterol is the major sterol in brassica oilseeds, followed by campesterol and brassicasterol.
With the exception of rapeseed oil, brassicasterol is not commonly found in plant-based oils. This makes it a relatively specific chemical marker for rapeseed (canola) oil and marine-sourced ingredients. Of more than 250 sterols and stanols known to exist in nature, only six — campesterol, campestanol, stigmasterol, sitosterol, sitostanol, and brassicasterol — are dominant in seed oils (rapeseed, soybean, corn, and sunflower oils), other grains (corn, rye, wheat, barley, millets, rice, oats, and peanuts), and tree oils.
Brassicasterol is a type of sterol that can be found in certain plants and seafood. Brassicasterol is a phytosterol found in marine algae, fish, and shellfish. Patent literature also records its presence in mollusks, particularly shellfish, and in the oils of certain Brassicaceae species such as Brassica rapa and Carthamus tinctorius. The appearance of brassicasterol in marine animals almost certainly reflects bioaccumulation from algal food sources rather than endogenous synthesis, since animals exclusively make C27 sterols, as they lack the ability to further modify C27 sterols to produce C28 and C29 sterols.
Brassicasterol is a minor constituent in most mixed phytosterol preparations. One representative gas chromatography characterization of a commercial phytosterol mixture found its composition to be β-sitosterol 46%, campesterol 25%, stigmasterol 21%, brassicasterol 3%, and other sterols 5%. The most abundant plant sterols overall are β-sitosterol (65%), campesterol (32%), and stigmasterol (3%).
In plant tissues, phytosterols occur in five common forms: free sterols, fatty-acid esters (steryl esters), steryl glycosides, acylated steryl glycosides, and hydroxycinnamic acid steryl esters. Brassicasterol participates in this same range of conjugated and unconjugated forms within its plant and algal sources.
At the commercial level, brassicasterol is not typically manufactured or sold as an isolated dietary supplement. There are no human trials examining the health benefit of brassicasterol when given as a supplement by itself, but it would make sense that brassicasterol would have similar physiological effects as other sterols such as sitosterol and stigmasterol. Instead, it is found as a minor component within broader phytosterol or plant-sterol ester preparations, which are fortified into food vehicles such as margarines, dairy spreads, yogurts, and salad dressings. As esters, sterols are lipid-soluble and are easily incorporated into yogurts, margarines, and salad dressings.
The main source of phytosterols in large-scale production is the by-products from the process of refining oils, known as deodorizer distillate (DD) or fatty acid distillate (FAD), which is a complex mixture of different compounds such as fatty acids, sterols, tocopherols, sterol esters, hydrocarbons, breakdown products of fatty acids, aldehydes, ketones, and acylglycerol species.
Brassicasterol does not have a documented history of isolation or deliberate use as a specific compound in any traditional medical system. Its presence in foods that have long cultural histories — notably members of the Brassica family (mustard, cabbage, rapeseed) and edible marine organisms — means it has been consumed as part of traditional diets across multiple cultures for centuries, but always as an unrecognized constituent of whole foods rather than as an intentionally administered phytochemical.
Notably, the seahorse (Hippocampus sp.) — a marine organism in which brassicasterol has been identified — does carry a long history of use in traditional East Asian medicine. In the Compendium of Materia Medica, seahorse (Hippocampus) is considered effective for the reinforcement of the kidney and men's health. However, the role of seahorse on human health lacks scientific evidence, and researchers have sought to evaluate its effect on human disease using in vitro methods and to identify its bioactive compounds. The attribution of any traditional benefits specifically to brassicasterol within such preparations has never been documented historically.
Rapeseed oil (canola oil), one of the richest dietary sources, has been cultivated in East Asia for over 2,000 years and in Europe since at least the 13th century, primarily as a lamp oil and, later, as an edible fat. Brassicasterol's presence in this oil was only characterized analytically in the modern era; there is no record of traditional practitioners recognizing or utilizing it specifically.
The scientific identification and naming of brassicasterol as a distinct chemical entity is a product of 20th-century sterol chemistry. Its biosynthetic relationship to brassinolide — a plant hormone with recognized growth-promoting activity isolated from Brassica napus pollen — was noted in the late 1970s and 1980s. From the pollen of Brassica napus L., brassinolide was found as a substance having a plant growth-promoting activity, and its chemical structure was identified. Brassicasterol is now recognized as a biosynthetic precursor in the brassinolide pathway in plants.
The primary pharmacological mechanism shared by all dietary phytosterols, including brassicasterol, is competitive displacement of cholesterol from intestinal mixed micelles. Different mechanisms, such as competition with cholesterol for solubilisation in dietary mixed micelles, co-crystallisation with cholesterol to form insoluble mixed crystals, and interference with the hydrolysis process by lipases and cholesterol esterases, are believed to contribute to the lowering of serum cholesterol concentrations by plant sterols. There is also emerging evidence that plant sterols interfere with transport-mediated processes of cholesterol uptake.
It has been shown that phytosterols inhibit cholesterol intake via cholesterol displacement from micelles, thus reducing the risk of cardiovascular diseases. Plant sterol administration leads to a reduction in total cholesterol and LDL-C levels by blocking dietary cholesterol absorption and further impacting its hepatic/intestinal biotransformation.
Brassicasterol possesses a biochemical mechanism that distinguishes it from the more abundant phytosterols β-sitosterol and campesterol: inhibition of the enzyme sterol Δ(24)-reductase in the endogenous cholesterol biosynthesis pathway. A published study in the journal Biochemical Journal (PMC1222779) demonstrated this in human cell lines:
Sterols containing a double bond at C-22 in the side chain — stigmasterol, brassicasterol, and ergosterol — dramatically inhibited the activity of sterol Δ(24)-reductase, as indicated by the decrease in radioactivity incorporation into cholesterol and the accumulation of its precursors (mainly desmosterol). Phytosterols with the saturated side chain (β-sitosterol and campesterol) were inactive in this regard.
The Δ22-unsaturated phytosterols acted as competitive inhibitors of sterol Δ(24)-reductase, with Ki values of 41.1, 42.7, and 36.8 µM for stigmasterol, brassicasterol, and ergosterol, respectively, similar to the estimated Km for desmosterol (26.3 µM). The usually low intracellular concentrations of the physiological substrates of Δ(24)-reductase explain the strong inhibition of cholesterol biosynthesis that these compounds exert in cells. This mechanism is cell-based (in vitro) and has not been directly confirmed in human clinical trials for brassicasterol specifically.
Dietary plant sterols taken up by the intestinal mucosa are largely excreted into the feces by adenosine triphosphate-binding cassette subfamily G members 5 (ABCG5) and 8 (ABCG8). NPC1L1, expressed on the apical surface of enterocytes, is responsible for the intestinal absorption of both cholesterol and plant sterols, whereas ABCG5/ABCG8 reduces dietary sterol concentration in the plasma by pumping plant sterols and "excess" cholesterol back into the intestinal lumen. These transporters are critical safety mechanisms that normally prevent accumulation of phytosterols in the body.
The anti-inflammatory properties of phytosterols involve the production of anti-inflammatory cytokines, the decrease in inflammatory mediator release, and the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). These pathways have been demonstrated for the phytosterol class broadly. Research specifically isolating brassicasterol from Phaeodactylum tricornutum has evaluated its anti-inflammatory effects under the chemical synonym 24-methylcholesta-5(6),22-diene-3β-ol (MCDO): the compound MCDO (identified in the literature as brassicasterol) was isolated from the hexane fraction of cultured P. tricornutum and evaluated for its anti-inflammatory effects both in vitro and in vivo.
Signaling pathway analysis showed that brassicasterol-treated HBV+ HCC cells had decreased levels of phospho-AKT expression, while the addition of an AKT agonist could counteract the inhibitory effect of brassicasterol on HCC, indicating that brassicasterol suppressed the AKT pathway to exhibit anti-cancer activity in HBV+ HCC cells.
Brassicasterol exerts an anti-cancer effect in AR-independent cancer as well as in AR-dependent cells by AKT inhibition. Findings from seahorse (H. abdominalis) lipid extract studies demonstrated that brassicasterol exerted an anti-cancer effect by dual-targeting AKT and AR signaling in prostate cancer. These findings are entirely preclinical.
In contrast with cholesterol, the structurally very similar dietary-derived plant sterols can enter the brain. Plant sterols may be natural activators of liver X receptors (LXRs). In contrast to peripheral cholesterol, plant sterols can cross the blood-brain barrier and accumulate within mammalian brain. The potential LXR-agonist activity of brassicasterol in the brain context remains exploratory.
Overview of evidence strength: Strong for the phytosterol class; no dedicated clinical trials for brassicasterol in isolation.
The cholesterol-lowering effect of phytosterols as a class is one of the most extensively replicated findings in nutritional science. A plethora of studies have explored distinct aspects of the clinical efficacy of plant sterols/stanols in lowering LDL-C levels, and there have been more than five decades of research on phytosterols to prove their efficacy in decreasing cholesterol levels.
A 2011 meta-analysis was conducted on 113 randomized controlled trials (RCTs) with a mean daily intake of 2.6 g of plant sterols and 1.8 g of plant stanol esters over four weeks. The variation in dose was linked to corresponding impacts on lipid profiles, with plant sterols leading to a 10.3% reduction in LDL cholesterol and plant stanol esters resulting in a 7.7% reduction. Overall, a daily intake of 2 g of sterols or stanol esters was associated with an 8.2% and a 9.3% reduction in LDL cholesterol, respectively.
An earlier meta-analysis of 84 RCTs found similar results. A total of 6,805 participants ate an average of 2.15 g of sterols or stanol esters over periods ranging from three weeks to six months. Overall, sterols and stanol esters lowered LDL cholesterol by 8.8%.
Clinical studies consistently indicate that the intake of phytosterols at 2 g/day is associated with a significant reduction (8–10%) in levels of LDL-cholesterol. Thus, several guidelines recommend the intake of 2 g/day of plant sterols and/or stanols in order to reduce LDL-cholesterol levels.
Regarding regulatory endorsement: a positive opinion on the scientific substantiation of health claims related to lowering blood cholesterol and reduced ASCVD risk after phytosterols was provided by a number of authorities, including the European Food Safety Authority (EFSA) in 2012. The European Atherosclerosis Society Consensus Panel agreed that a 2 g/day intake of phytosterols leads to a 10% reduction in serum LDL-C, decreasing the risk of cardiovascular disease without side effects.
Important caveat: The absence of clinical trials showing that phytosterol intake can reduce the incidence of clinical endpoints, such as myocardial infarction or coronary deaths, needs to be acknowledged. Although phytosterols decrease LDL-cholesterol levels, there is no evidence that they reduce the risk of cardiovascular diseases; on the contrary, some studies suggest an increased risk of atherosclerosis with increasing serum levels of phytosterols.
Because brassicasterol is only a minor constituent of phytosterol blends used in these studies, its individual contribution to LDL reduction in humans cannot be isolated from existing trial data.
Overview of evidence strength: Preliminary; in vitro and animal models only — no human clinical evidence for brassicasterol specifically.
Phytosterols have an inhibitory effect on lung, stomach, breast, ovarian, and colorectal cancers mediated via multiple mechanisms, including modification of cell membrane structure and function, as well as an increase in cancer cell apoptosis by lowering blood cholesterol levels. The biochemical and molecular effects of plant sterols also make them strong candidates for breast cancer therapy.
Specific preclinical studies on brassicasterol in cancer models include:
All cancer-related findings for brassicasterol are preclinical (cell-line and mouse xenograft models). No clinical trials in human cancer patients have been conducted using isolated brassicasterol.
Overview of evidence strength: Preliminary; predominantly preclinical.
Brassicasterol isolated under its synonym MCDO from the marine diatom Phaeodactylum tricornutum has been tested for anti-inflammatory activity in laboratory studies. The compound was evaluated for its anti-inflammatory effects in vitro and in vivo. The broader class of 4-demethyl phytosterols to which brassicasterol belongs has been shown to exhibit antiviral, anti-inflammatory, and anticancer activities. No published randomized controlled trials in humans specifically examining brassicasterol's anti-inflammatory effects were identified.
Overview of evidence strength: Exploratory; one published observational case-control study; no therapeutic trials.
Plant sterols — sitosterol, campesterol, stigmasterol, and brassicasterol — are solely dietary-derivable sterols that are structurally very similar to cholesterol. In contrast to peripheral cholesterol, plant sterols can cross the blood-brain barrier and accumulate within mammalian brain.
A case-control study published in Acta Psychiatrica Scandinavica (Vanmierlo et al., 2011) measured plant sterol concentrations in plasma and CSF of patients with Alzheimer's disease (AD) and controls: gas chromatography/mass spectrometry analysis was applied to plant sterol concentrations measured in plasma and CSF of patients with AD (n = 67) and controls (n = 29). Comparison of lipid parameters revealed significantly lower concentrations of brassicasterol (P <0.001) in the CSF of patients with AD. Binary logistic regression analysis revealed that brassicasterol improved the predictive value when added to pTau and Aβ(42) in a biomarker model. The authors concluded that brassicasterol might be a relevant additional biomarker in AD.
Recent findings strengthen the link between brain cholesterol metabolism and factors involved in synaptic plasticity — a process essential for learning and memory functions — as well as regeneration, which are affected in Alzheimer's disease. Cholesterol homeostasis within the brain is independent of that in the rest of the body and needs to be strictly regulated for optimal brain functioning. The potential relationship of brassicasterol to this axis is being studied; however, it is important to note that the reported finding is associative (lower CSF brassicasterol in AD patients) rather than demonstrating that brassicasterol supplementation prevents or treats AD. No therapeutic trials exist.
A well-established, non-therapeutic application of brassicasterol is its use as a scientific proxy or biomarker in paleoceanography and environmental chemistry. Its relatively high concentration and stability allows it to be used in the assessment of the origin of organic matter in samples, especially sediments. In marine organic matter, brassicasterol and dinosterol have been associated with a wide range of algal groups such as diatoms and dinoflagellates, and have often been used as open-water phytoplankton biomarker proxies. Researchers reconstruct past climate and oceanographic conditions using sedimentary brassicasterol records spanning geological time periods.
No clinical studies have been published that administer isolated brassicasterol as a standalone supplement to human subjects. There are no human trials examining the health benefit of brassicasterol when given as a supplement by itself.
Brassicasterol is consumed by humans as a minor component of phytosterol-containing foods and supplements. The dosage data below pertain to total phytosterol mixtures (of which brassicasterol may be a minor fraction, typically ~1–3% of the total sterol content):
Because brassicasterol constitutes only approximately 3% of most commercial phytosterol preparations (based on available compositional analyses), a 2 g/day phytosterol dose would contain roughly 40–60 mg of brassicasterol — a figure derived by calculation, not by direct measurement in any published study.
Although plant sterols, once absorbed, can promote atherosclerosis, their intake is believed to be safe because of poor absorption, except in rare hyperabsorbers with homozygous ABCG5/8 mutations. Consuming phytosterol-enriched foods increases plant sterol concentrations by approximately 35%. On a molar basis, phytosterols would need to have 20–40 times higher atherogenicity than cholesterol to offset their cholesterol-reduction benefit.
Phytosterolemia, also known as sitosterolemia, is a rare autosomal-recessively inherited disease resulting from mutations in either the ABCG5 or ABCG8 genes. Individuals who are homozygous for phytosterolemia typically exhibit a greater than 30-fold increase in plasma phytosterol concentrations and deposition of sterols in skin and tendons (xanthomas). Consuming plant sterols is contraindicated in individuals homozygous for phytosterolemia. In patients with homozygous phytosterolemia, a rare genetic disease, the excretion of phytosterols from the body is hampered due to a loss of function of the ATP-binding cassette transporters ABCG5 and ABCG8, caused by genetic mutations. This leads to very high plasma concentrations of phytosterols in patients with this disease. These patients often (though not always) display premature atherosclerosis and coronary artery disease.
Observational studies show no evidence that plasma phytosterol concentrations would be associated with an increased risk of atherosclerosis or cardiovascular events. However, a genuine scientific debate exists: although phytosterols decrease LDL-cholesterol levels, there is no evidence that they reduce the risk of cardiovascular diseases; on the contrary, some studies suggest an increased risk of atherosclerosis with increasing serum levels of phytosterols. Clinical benefits of phytosterols have not been established in long-term cardiovascular endpoint studies.
The same micellar mechanism by which phytosterols inhibit cholesterol absorption can also reduce the absorption of fat-soluble carotenoids (β-carotene, lycopene, α-carotene) and fat-soluble vitamins. This has been noted across the phytosterol class and is relevant to any preparation containing brassicasterol as part of a phytosterol mixture. This concern is documented in the broader phytosterol safety literature; whether brassicasterol specifically, at low doses, contributes meaningfully to carotenoid depletion has not been individually studied.
In 2020, the EFSA released a statement that the safety of plant sterol oxidation products caused by heating plant sterol esters (e.g., in vegetable fat spreads) during cooking and baking remained unestablished. This concern applies generically to all phytosterol esters and their application to food processing.
Once absorbed, plant sterols can promote atherosclerosis, as observed in patients with sitosterolemia. In patients with diabetes, although some studies suggest increased plant sterol absorption, there is no direct evidence of its changes in response to treatment of hyperglycemia. Therefore, it is unclear whether the recommendation to increase plant sterol consumption is safe for every patient with diabetes.
The cholesterol-absorption inhibitor ezetimibe (a pharmaceutical drug acting on NPC1L1) is known to reduce plasma phytosterol concentrations, including brassicasterol. This is relevant in individuals with elevated phytosterol levels: the addition of ezetimibe normalizes plant sterol levels in cases of plant sterol hyperabsorption, including those associated with ABCG5/ABCG8 mutations and potentially uncontrolled diabetes.
Brassicasterol is a structurally well-characterized phytosterol that occurs naturally in Brassica oilseeds, marine algae, and seafood. It participates in the same general biological mechanisms as the phytosterol class — most importantly, the inhibition of intestinal cholesterol absorption. Uniquely among the common phytosterols, its C-22 double bond enables it to act as a competitive inhibitor of sterol Δ(24)-reductase in the cholesterol biosynthesis pathway, a mechanism demonstrated in human cell lines.
Preclinical research (cell lines and animal models) has identified anti-cancer activity against hepatocellular carcinoma and prostate cancer, anti-inflammatory effects, and anti-infective actions against HSV-1 and M. tuberculosis. A case-control study in 96 subjects has raised the possibility of brassicasterol as an additional CSF biomarker in Alzheimer's disease. None of these areas have yet been evaluated in human clinical trials using brassicasterol as a standalone compound.
The substantial clinical evidence base for LDL cholesterol reduction — spanning more than 100 RCTs and endorsed by EFSA, the European Atherosclerosis Society, and other bodies — pertains to phytosterol blends in which brassicasterol is a minor and variable component. It cannot be directly attributed to brassicasterol alone.
Health conditions that Brassicasterol may help support.
Phytosterols including brassicasterol have been characterised in preclinical studies as modest radical scavengers and membrane lipid oxidation stabilizers. Sterol-rich fractions from microalgae (which are enriched in brassicasterol) demonstrate DPPH and ABTS radical scavenging activity. Evidence is entirely preclinical (in vitro and cell-based); no human clinical trials specifically assessing brassicasterol's antioxidant effects have been conducted.
Brassicasterol, as part of phytosterol mixtures, has been associated with reduced aortic atherosclerotic lesion burden in animal models of hypercholesterolaemia. In humans, the phytosterol class reduces LDL-C, which is mechanistically linked to reduced arterial plaque formation; however, evidence that phytosterols reduce clinical cardiovascular endpoints (e.g., MI, stroke) remains inconsistent. Elevated plasma phytosterol levels have also been associated with lower frequency of cardiometabolic risk factors in observational studies.
Brassicasterol is a plant sterol abundant in canola oil and Brassica vegetables that inhibits intestinal cholesterol absorption as part of the phytosterol class. It shares the EFSA-recognized health claim for plant sterols and the same LDL-C-lowering mechanism.
Brassicasterol is a phytosterol whose class has well-documented LDL-cholesterol-lowering effects in human clinical studies. Phytosterol intake of ≥2 g/day is endorsed by EFSA and the European Atherosclerosis Society as a cholesterol-lowering strategy. By reducing LDL-C, phytosterols including brassicasterol are positioned as adjunctive tools for cardiovascular risk reduction, though direct randomized endpoint trials for brassicasterol alone are lacking.
Brassicasterol isolated from seahorse (Hippocampus abdominalis) demonstrated specific anti-cancer activity in androgen-dependent prostate cancer cell lines (LNCaP) in vitro, downregulating androgen receptor (AR) and PSA expression and inducing apoptosis. The mechanism involves dual inhibition of AKT and AR signaling pathways. This evidence is currently limited to in vitro cell studies; no human clinical trials exist.
Body systems that Brassicasterol may help support.
Go back